🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Canada to shrug off 'momentary disruptions' in vaccine supply, working closely with U.S. - Trudeau

Published 2021-02-04, 06:58 p/m
© Reuters.
PFE
-
AZN
-

By Steve Scherer and Allison Martell

OTTAWA (Reuters) - Canada will succeed in inoculating its population despite "momentary disruptions" in the supply of COVID-19 vaccines and is working closely with the new U.S. administration to fight the disease, Prime Minister Justin Trudeau said on Thursday.

Trudeau's Liberal government is under pressure over the slow roll out of the vaccination program, caused in part by Pfizer Inc (NYSE:PFE) temporarily cutting its promised deliveries and a temporary slowdown of Moderna Inc doses.

"Obviously with this global supply chain around new products and manufacturing scale-ups ... there are momentary disruptions week over week. But we're still very much on track to get the commitments fulfilled and get many vaccines to Canadians as quickly as possible," Trudeau said in an interview.

Trudeau promised that tens of millions of doses would arrive in the months to come and reiterated that every Canadian seeking inoculation would be vaccinated by September.

As part of a bid to contain the spread of the disease, Canada and the United States have closed their joint border to non-essential travel. Trudeau said he and new U.S. President Joe Biden agreed on a joint approach to fighting COVID-19.

"We're working very, very closely on all aspects of it from borders to scientific research to indeed vaccines," he said.

"Our conversations are going to continue with the U.S. on supply chains," he said, without giving details. Last year, tensions arose between Canada and the administration of then President Donald Trump over delays in the supply of personal protective equipment.

Last year Trump also signed an executive order aimed at keeping U.S.-produced vaccines in the United States. Trudeau did not give a direct answer when asked whether he would press Biden to scrap the order.

Canada does not yet have a vaccine manufacturing facility of its own and is reliant on foreign suppliers.

Separately, federal Procurement Minister Anita Anand said deliveries of AstraZeneca (NASDAQ:AZN) Plc's COVID-19 vaccine could begin before the end of March, if Canada's health regulator approves its use.

AstraZeneca Canada filed a rolling application for its vaccine with Health Canada in October and is waiting for approval from the drug regulator. Health Canada is expected to complete its review soon.

In a separate briefing, federal officials confirmed Canada's most recent shipment of Moderna Inc's COVID-19 vaccine contained 22% fewer doses than originally expected and said the next shipment, due in three weeks, would also be short.

Fortin added Moderna was working in "good faith" to deliver those doses as quickly as possible to Canada and noted the obstacles would be temporary.

Shipments of Pfizer Inc's vaccine, meanwhile, are expected to ramp up later this month.

Trudeau's government is also facing criticism over tapping into COVAX, a global vaccine-sharing initiative meant to help low-income countries buy doses. Canada will get 1.9 million AstraZeneca doses from the initiative.

© Reuters. FILE PHOTO: Canada's Prime Minister Justin Trudeau attends a news conference in Ottawa

"Our government will never apologize for doing everything possible to get Canadians vaccinated as quickly as possible," Deputy Prime Minister Chrystia Freeland told lawmakers.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.